Victory Capital Management
SYRE icon

Victory Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Victory Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.2M Buy
553,980
+261,854
+90% +$19.1M 0.03% 586
2026
Q1 		$14.7M Buy
292,126
+146,047
+100% +$5.51M 0.01% 972
2025
Q4 		$4.79M Sell
146,079
-180,002
-55% -$4.7M ﹤0.01% 1333
2025
Q3 		$5.47M Sell
326,081
-28,035
-8% -$457K ﹤0.01% 1314
2025
Q2 		$5.3M Buy
354,116
+102,270
+41% +$1.51M ﹤0.01% 1302
2025
Q1 		$4.06M Sell
251,846
-16,230
-6% -$338K ﹤0.01% 1345
2024
Q4 		$6.24M Buy
+268,076
New +$7.86M 0.01% 1213
2020
Q2 		– Sell
-171
Closed -$20K – 3209
2020
Q1 		$20K Buy
+171
New +$29.1K ﹤0.01% 2845
2019
Q4 		– Sell
-189
Closed -$36K – 3218
2019
Q3 		$36K Buy
+189
New +$36.8K ﹤0.01% 2825

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Victory Capital Management's SYRE Position: Q2 2026 in Review

Victory Capital Management increased its Spyre Therapeutics (SYRE) stake by 90% in Q2 2026, buying an estimated $19.1M and bringing the position to 553,980 shares worth $49.2M. The position accounts for 0.03% of the portfolio, ranked #586.

Victory Capital Management first reported a position in SYRE in Q3 2019 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Victory Capital Management held 553,980 shares of Spyre Therapeutics worth $49.2M as of Q2 2026.
  • Victory Capital Management bought 261,854 Spyre Therapeutics shares in Q2 2026, an estimated $19.1M.
  • Spyre Therapeutics made up 0.03% of Victory Capital Management's portfolio in Q2 2026, its #586 holding.
  • Victory Capital Management first reported a position in Spyre Therapeutics in Q3 2019 and has held it in 9 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.